Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DML8N3Y)

Drug Name
Recifercept Drug Info
Synonyms TA-46
Indication
Disease Entry ICD 11 Status REF
Achondroplasia LD24.00 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DML8N3Y

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor receptor 3 (FGFR3) TTST7KB FGFR3_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Fibroblast growth factor receptor 3 (FGFR3) DTT FGFR3 6.541 6.15 4.087 6.471
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Achondroplasia
ICD Disease Classification LD24.00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fibroblast growth factor receptor 3 (FGFR3) DTT FGFR3 5.83E-03 0.08 0.1
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04638153) A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia. U.S. National Institutes of Health.
2 In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368.